Jubilant Pharmova Ltd. (JUBLPHARMA)

Overview

Jubilant Pharmova Limited stands as a pivotal integrated pharmaceutical and life sciences entity within India, extending its reach across the Americas, Europe, and other international markets. The company prides itself on a diversified operational spectrum, categorized into six key segments: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Generics, Contract Research Development & Manufacturing Organisation (CRDMO), and Proprietary Novel Drugs. Initially known as Jubilant Life Sciences Limited, the entity underwent a rebranding to Jubilant Pharmova Limited in February 2021, a reflection of its evolving identity and expanded focus. Since its inception in 1978, headquartered in Noida, India, Jubilant Pharmova Limited has continually pushed the boundaries in pharmaceutical innovation and service.

Products and Services

• Radiopharma

  Specializes in the production of radiopharmaceutical products utilized in diagnosing and treating a diverse array of diseases such as pulmonary embolism, various cancer types, coronary artery disease, and others. This segment leverages advanced radioisotope applications to contribute significantly to the fields of oncology and cardiology, enhancing patient care and treatment outcomes.

• Allergy Immunotherapy

  Delivers specialized diagnostic tools for skin testing and venom immunotherapy products. This suite of products is aimed at identifying and treating allergies, providing critical solutions in the realm of immunotherapy. Through its offerings, Jubilant Pharmova Limited enables healthcare professionals to offer precision-based allergy treatments.

• CDMO Sterile Injectables

  Provides extensive contract manufacturing services focusing on sterile fill and finish injectables, including liquids, ointments, creams, and ampoules. This segment supports pharmaceutical companies by ensuring high-quality production of sterile formulations, adhering to stringent regulatory standards.

• Generics

  Engages in the development, manufacturing, distribution, sale, and marketing of solid dosage formulations across various therapeutic areas such as the cardiovascular system, central nervous system, gastrointestinal, and multispecialty. The Generics segment aims to improve global health by offering affordable and effective medication options.

• Contract Research Development & Manufacturing Organisation (CRDMO)

  Offers comprehensive drug discovery and development services alongside the provision of active pharmaceutical ingredients (APIs). This segment stands as a cornerstone in fostering innovation and spearheading the development of next-generation pharmaceutical products.

• Proprietary Novel Drugs

  Focuses on the development of innovative therapies in the critical areas of oncology and auto-immune diseases. With a commitment to addressing unmet medical needs, the Proprietary Novel Drugs segment underscores Jubilant Pharmova Limited’s investment in research and development to bring forth novel treatment options.